Pharmaceuticals, Biotechnology and Life Sciences
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the…
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the…
While Both iStent and iStent inject Showed Significant IOP and Medication Reduction in Combo-Cataract Procedures at 1 Year Postoperative, iStent…
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the…
Glaukos will establish a new R&D retinal program that
complements our growing glaucoma franchise and pipeline.
standalone implantation of two iStent®Trabecular Micro-Bypass Stents in newly diagnosed primary open-angleglaucoma (POAG) eyes achieved a 35.3% reduction in meanintraocular pressure (IOP) to 16.5 mmHg after five years of follow-up.
Study Published in Ophthalmology Demonstrates Significant, SustainedClinical Benefit and Confirms Favorable Safety Profile forNext-Generation Device Approved by FDA in June 2018